Company intelligence / Profile preview

LASEREDD Therapeutics

Melbourne, Victoria, Australiapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

LASEREDD Therapeutics leverages its proprietary LASEREDD® platform to discover novel therapeutic antibodies targeting previously inaccessible biological targets. The company has secured seed investment to advance its drug discovery efforts, with an initial focus on schizophrenia. There are references to broader ambitions in oncology and cardiology, but schizophrenia appears to be the lead indication at this stage

Therapeutic areas: OncologyPsychiatryCardiovascular
Modalities: Therapeutic antibodies
Industry: Biotech

Partnerships

Curie.Biopossible academic partnership with The Florey Institute given spin-out origin

Beyond the preview

Go deeper on LASEREDD Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LASEREDD Therapeutics.

Explore the full profile